Use of polylactic acid in face lipodystrophy in HIV positive patients undergoing treatment with antiretroviral drugs (HAART)

Acta Chirurgiae Plasticae

Volumn 46, Issue 1, 2004, Pages 12-15

  Onesti, M G ^a   Renzi, L F ^a,b   Paoletti, F ^a   Scuderi, N ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

AIDS; Facial wasting; HIV; Infiltration; Lipodystrophy; Polylactic acid

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; POLYLACTIC ACID; RITONAVIR; STAVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DOCUMENTATION; FACE DISORDER; FAMILY; FEMALE; FOLLOW UP; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MALE; MEDICAL PHOTOGRAPHY; PATIENT SATISFACTION; TREATMENT OUTCOME; WEIGHT REDUCTION; WELLBEING; WORK ENVIRONMENT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOCOMPATIBLE MATERIALS; FACE; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; POLYMERS;

EID: 2942536250     PISSN: 00015423     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Carr, A., Samras, K., Chisolm, DJ., Cooper, DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet, 353, 1999, p. 2093-2099.
2. Saint-Marc, T., Partisani, M., Poizot-Martin, I. et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS, 14, 2000, p. 37-49.
3. Del Pino, V., Arèvalo, JM., Moreno, S., Dronda, F. Successful surgical therapy with polyvinyl gel microspheres of severe facial lipoathrophy: results after 1 year follow-up. Antiv. Therapy, 6, 2001, 4, p. 36.
4. Guaraldi, G. et al. Autologous fat transfer for treating facial wasting in HIV body fat redistribution syndrome. Abst. On 3rd European Workshop on Lipodystrophy and Methabolic Disorders, Marbella, Apr. 2002.
5. Aubron, O. et al. Benefit of polylactic acid implant (new-fill) in severe facial lipoathrophy in HIV infected patients: preliminary results of the Vega study. 8th Conference on Clinical Aspects and Treatment of HIV infections. Abstr. 020, Athens, 2001.
6. Polo, L. et al. The effects of polylactic acid in the therapy for the lipoatrophy of the face. Antiv. Therapy, 6, 2001, 4, p. 68.
7. Amard, P. et al. The effects of polylactic acid (PLA) as therapy for lipoathrophy of the face. Toronto: Lipodystrophy Workshop, Sept. 13-15, 2000.
8. Onesti, MG., Latini, C., Spalvieri, C. Complicanze legate all'uso del silicone liquido: nostra esperienza. Atti 48th National SICPRE Congress, Guggio Sept. 25-30, 1999, p. 701-706.
9. Gogolewski, S., Jovanovic, M., Perren, SM. et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (P.L.A.), poly(3-hydroxybutyrate) (P.H.B.), and poly(3-hydroxybutirate-co-3-hydroxyvalerate) (P.H.B./VA). J. Biomed. Mater. Res., 27, 1993, 9, p. 1135-1148.
10. Onesti, MG., Renzi LF., Scuderi, N. Applicazioni cliniche del New-Fill® in chirurgia plastica ricostruttiva ed estetica. Studio Preliminare. La Medicina Estetica, 26, 2002, 2, p. 283-286.